 |
|
 |
|
| MarketVIEW: Chikungunya virus vaccines |
|
|
|
Published: 2021
Travel/other segment forecast now updated!, 2023
Chikungunya virus (CHIK) is an arthropod-borne RNA virus (arbovirus) which causes an acute illness including fever, skin rash, and incapacitating arthralgia.
In some cases, the virus can cause recurrent disease (post-CHIK rheumatic disorder), neurological complications and severe neonatal disease (encephalopathy). CHIK is not generally considered a life-threatening disease, with an estimated case-fatality rate of 0.1%.
However, concerns are increasing. In 2023, so far, there has been 184,572 confirmed cases of CHIK across the PAHO region with Brazil and Paraguay being key countries (WHO PLISA). The outbreak in Paraguay caused 272 deaths indicating a high potential mortality burden for future outbreaks.
A number of potential CHIKV vaccine candidates (based on various approaches) are now in various stages of clinical development including those from Emergent BioSolutions (PXVX0317 VLP now acquired by Bavarian Nordic), Bharat Biotech and Valneva Austria GmbH (VLA1553, IXCHIQ)
These candidates have received US and EU fast track regulatory designations along with support from The Coalition of Epidemic Preparedness Innovations (CEPI) underscoring their high medical need. IXCHIQ has now received US FDA approval in persons >18 yrs (November 2023) and expected to receive US ACIP recommendations for use in travelers, Spring 2024. A label-extension clinical study in adolescents (Instituto Butantan) is ongoing in Brazil which could support licensure in that country.
This MarketVIEW product is a comprehensive commercial evaluation containing an Executive Presentation (>250 slides) and 1 x MS Excel Workbook(s) (.xls) examining the potential (value/volume) of a prophylatic Chikungunya vaccine to 2035.
The prospects of the vaccine in First time and Repeat Western travelers (Visiting Friends/Family and Business + Other), endemic markets (public + private) and for military/domestic stockpile use are discussed with assumptions clearly outlined.
A newly engineered model for June 2023 now explores a mixed vaccine schedule market and brand new competitor entrance scenarios.
A full review of disease background, latest epidemiology/outbreaks and competitor/R&D activity is also provided.
THIS PRODUCT IS A SUMMARY PRESENTATION (>250 slides, .pdf form) + 1 x FORECAST MODEL(s) (.xls)
To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW.
For UK orders VAT will be added at 20%. On-line prices may include discounts and are converted from list price in US dollars (subject to currency fluctuations).
Please review the TERMS and CONDITIONS of purchase.
|
|
|
|
|
|
